Roche?s Erivedge receives conditional EU approval for treatment of advanced basal cell carcinoma
March 3, 2014 
0 Comments
Erivedge is a new medicine that helps people with a disfiguring and potentially life-threatening form of skin cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted conditional approval to Erivedge (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or Read more